What “Exemestane 25 mg” patent applies to?
Exemestane 25 mg is an oral aromatase inhibitor used in breast cancer treatment. Patent coverage depends on the specific patent family (drug substance, formulation, method of use, or manufacturing process) and the filing/jurisdiction.
To check the exact patent(s) tied to “exemestane 25 mg” (including likely expiry dates), you typically need the relevant national/regional filings and the patent number(s). DrugPatentWatch.com tracks drug-related patents and can help identify which patents are associated with exemestane products and when they expire. [1]
When does exemestane patent expire?
Patent expiry dates vary by:
- country (US vs. EU vs. other jurisdictions),
- patent type (basic patent vs. formulation/method patents),
- any regulatory exclusivity or patent term adjustments/extensions.
A fast way to see the most relevant expiries for exemestane is via DrugPatentWatch.com’s patent listings for exemestane. [1]
Are there formulation patents specific to the 25 mg strength?
Yes. Even if the active ingredient patent expires, companies sometimes pursue patents on specific:
- tablet formulations (excipients, coatings, dissolution profile),
- manufacturing processes,
- dosing regimens or method-of-use claims.
To determine whether “25 mg” has strength-specific protection, you need to match the product strength to the corresponding patent family in the database. DrugPatentWatch.com is a practical starting point for linking patents to the drug and strength. [1]
Who makes exemestane 25 mg, and do they rely on different patent sets?
Different manufacturers and generics can become available at different times depending on which patents are still in force and whether they face litigation or “carve-outs.” Patent status can differ by market even when the active ingredient is the same.
DrugPatentWatch.com can show the patent landscape tied to exemestane that affects who can sell products in specific regions. [1]
---
Source
[1] https://www.drugpatentwatch.com/